Search peptides, terms, sources/
8 peptides

Growth hormone axis

Growth hormone axis peptides are studied for how they change the amount of growth hormone the body releases. Most act on the pituitary gland. Some mimic growth-hormone-releasing hormone and others act on the ghrelin receptor. The evidence differs widely in age, size and quality between peptides. Membership of the group reflects a shared mechanism, not equal evidence.

Which peptides are in this family?

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CJC-1295CJC-1295 with DAC

    Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • IpamorelinIPA

    Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK

Best recorded finding for each peptide in this family

Each row grades one recorded finding, not the peptide or the medicine.

PeptideUK statusFindingEvidence grade
AOD-9604Not licensed in the UKSix pooled Phase I/II trialsModerate
CJC-1295Not licensed in the UKGrowth hormone and IGF-1 elevationLimited
GHRP-2Not licensed in the UKAdult GH deficiency test, JapanLimited
GHRP-6Not licensed in the UKPhase I pharmacokinetics, nine menLimited
HexarelinNot licensed in the UKAmount-dependent GH, cortisol, prolactinLimited
IpamorelinNot licensed in the UKHealthy male pharmacokinetic studyLimited
SermorelinNot licensed in the UK1999 review, childhood GH deficiencyLimited
TesamorelinNot licensed in the UKHIV visceral fat trialStrong

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.